07:25 AM EDT, 07/02/2025 (MT Newswires) -- Instil Bio ( TIL ) said Wednesday that the US Food and Drug Administration has cleared its investigational new drug application for AXN-2510, a bispecific antibody that targets relapsed solid tumors in non-small cell lung cancer.

The company said it plans to conduct an early-stage trial in patients with relapsed or refractory solid tumors by the end of the year, the company said.

The study will assess safety, efficacy, pharmacokinetics, and pharmacodynamics of the drug candidate, Instil said.

Instil also said that ImmuneOnco plans to report preliminary results from a separate mid-stage trial in NSCLC patients in China later this year.

Shares of the company were up 10% in recent Wednesday premarket activity.